

Emanuele Durante Mangoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4972145/publications.pdf>

Version: 2024-02-01

153
papers

5,988
citations

81434

41
h-index

90395

73
g-index

174
all docs

174
docs citations

174
times ranked

7402
citing authors

#	ARTICLE	IF	CITATIONS
1	InÂvivo fitness of carbapenem-resistant <i>Acinetobacter baumannii</i> strains in murine infection is associated with treatment failure in human infections. <i>Clinical Microbiology and Infection</i> , 2022, 28, 73-78.	2.8	1
2	Drugs and liver injury: a not to be overlooked binomial in COVID-19. <i>Journal of Chemotherapy</i> , 2022, 34, 207-220.	0.7	3
3	Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of <i>Clostridioides difficile</i> Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. <i>Antibiotics</i> , 2022, 11, 183.	1.5	16
4	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 934-943.	1.3	5
5	Prognostic Value of Decreased High-Density Lipoprotein Cholesterol Levels in Infective Endocarditis. <i>Journal of Clinical Medicine</i> , 2022, 11, 957.	1.0	2
6	Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. <i>Journal of Chemotherapy</i> , 2022, 34, 360-366.	0.7	4
7	Dissecting the correlates of N-terminal prohormone brain natriuretic peptide in acute infective endocarditis. <i>Infection</i> , 2022, 50, 1465-1474.	2.3	5
8	Risk factors for gram-negative infection of cardiovascular implantable electronic devices: retrospective multicenter study - CarDINE study. <i>Europace</i> , 2022, 24, .	0.7	0
9	Dalbavancin for infective endocarditis: a single centre experience. <i>Journal of Chemotherapy</i> , 2021, 33, 256-262.	0.7	11
10	Enterococcal infective endocarditis is a marker of current occult or future incident colorectal neoplasia. <i>European Journal of Internal Medicine</i> , 2021, 83, 68-73.	1.0	5
11	Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs. <i>Journal of the American College of Cardiology</i> , 2021, 77, 544-555.	1.2	36
12	Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis. <i>BMC Infectious Diseases</i> , 2021, 21, 23.	1.3	10
13	Associating enterococcal endocarditis and colorectal neoplasia: is colonoscopy mandatory? â€œ Authorsâ€™ reply. <i>European Journal of Internal Medicine</i> , 2021, 85, 114-115.	1.0	0
14	Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2021, 23, e13595.	0.7	16
15	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. <i>BMC Infectious Diseases</i> , 2021, 21, 309.	1.3	4
16	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 1569.	1.0	7
17	Infective Endocarditis in Patients on Chronic Hemodialysis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1629-1640.	1.2	23
18	Cardiac complications during the active phase of COVID-19: review of the current evidence. <i>Internal and Emergency Medicine</i> , 2021, 16, 2051-2061.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Parsimonious Use of Antibiotics in COVID-19: A Missed Opportunity. <i>Clinical Infection and Immunity</i> , 2021, 6, 29-30.	0.1	2
20	Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center Experience. <i>Microorganisms</i> , 2021, 9, 1210.	1.6	6
21	Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. <i>Life</i> , 2021, 11, 519.	1.1	31
22	Predictors of long-term mortality in left-sided infective endocarditis: an historical cohort study in 414 patients. <i>European Journal of Internal Medicine</i> , 2021, 94, 27-33.	1.0	4
23	Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience. <i>Microbial Drug Resistance</i> , 2021, 27, 1167-1175.	0.9	43
24	Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1250-1261.	2.8	69
25	Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites. <i>Infezioni in Medicina</i> , 2021, 29, 434-449.	0.7	2
26	Clinical Significance and Prognostic Value of Hemostasis Parameters in 337 Patients with Acute Infective Endocarditis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5386.	1.0	4
27	Diagnostic and infection control strategies for <i>Clostridioides difficile</i> infections in a setting of high antimicrobial resistance prevalence. <i>Infezioni in Medicina</i> , 2021, 29, 70-78.	0.7	0
28	International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated <i>Mycobacterium chimaera</i> Infection Following Cardiac Surgery with Cardiopulmonary Bypass. <i>Journal of Hospital Infection</i> , 2020, 104, 214-235.	1.4	50
29	Reply to Wilson et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 1358-1359.	2.9	0
30	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. <i>Clinical Infectious Diseases</i> , 2020, 71, 2599-2607.	2.9	10
31	Current trends in the real-life use of dalbavancin: report of a study panel. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106107.	1.1	16
32	Liver injury in remdesivir-treated COVID-19 patients. <i>Hepatology International</i> , 2020, 14, 881-883.	1.9	96
33	Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study. <i>Brain Sciences</i> , 2020, 10, 483.	1.1	12
34	Low rate of severe acute respiratory syndrome coronavirus 2 spread among health-care personnel using ordinary personal protection equipment in a medium-incidence setting. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1269-1270.	2.8	18
35	Early experience with remdesivir in SARS-CoV-2 pneumonia. <i>Infection</i> , 2020, 48, 779-782.	2.3	23
36	Real-life experience with ceftobiprole in a tertiary-care hospital. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 386-390.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa120.	0.4	12
38	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1185-1191.	2.8	46
39	Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1644-1650.	2.8	22
40	Does this patient have COVID-19? A practical guide for the internist. <i>Internal and Emergency Medicine</i> , 2020, 15, 791-800.	1.0	15
41	Liver histopathological findings in advanced heart failure: a reappraisal of cardiac cirrhosis concept. <i>Internal and Emergency Medicine</i> , 2019, 14, 931-940.	1.0	2
42	Management of carbapenem-resistant Enterobacteriaceae infections. <i>Clinical Microbiology and Infection</i> , 2019, 25, 943-950.	2.8	142
43	Hepatitis B core-related antigen to detect hepatitis B virus (HBV) reactivation in heart transplant recipients with past HBV infection: A pilot study. <i>Clinical Transplantation</i> , 2019, 33, e13574.	0.8	3
44	The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis. <i>European Heart Journal</i> , 2019, 40, 2243-2251.	1.0	32
45	Dynamics and management of oral anticoagulant treatment in chronic hepatitis C patients undergoing therapy with direct antiviral agents. <i>Journal of Chemotherapy</i> , 2019, 31, 86-89.	0.7	0
46	Prevention and control of intensive care unit-acquired carbapenem-resistant <i>Klebsiella pneumoniae</i> : need for a multimodal approach. <i>Annals of Translational Medicine</i> , 2019, 7, S325-S325.	0.7	2
47	Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility. <i>Clinical Microbiology and Infection</i> , 2019, 25, 711-716.	2.8	23
48	Treatment Outcomes of Colistin- and Carbapenem-resistant <i>Acinetobacter baumannii</i> Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 769-776.	2.9	83
49	Association between the timing of surgery for complicated, left-sided infective endocarditis and survival. <i>American Heart Journal</i> , 2019, 210, 108-116.	1.2	24
50	Infective Endocarditis in the Elderly: Diagnostic and Treatment Options. <i>Drugs and Aging</i> , 2019, 36, 115-124.	1.3	20
51	Colistin versus colistin plus meropenem for severe infections Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 495-496.	4.6	1
52	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1070-1076.	2.8	58
53	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 391-400.	4.6	400
54	Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	56

#	ARTICLE	IF	CITATIONS
55	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. <i>Journal of Chemotherapy</i> , 2018, 30, 157-171.	0.7	0
56	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1815-1823.	2.9	29
57	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	1.0	29
58	Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases. <i>Journal of Chemotherapy</i> , 2018, 30, 129-130.	0.7	1
59	Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12813.	0.7	6
60	Effect of a Cooperation Strategy between Primary Care Physicians and Hospital Liver Units on HBV Care in Campania, Italy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-6.	0.8	2
61	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 25.	0.5	15
62	Viability of pegIFN α -RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment. <i>Journal of Chemotherapy</i> , 2017, 29, 94-101.	0.7	1
63	Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible <i>Staphylococcus aureus</i> left-sided infective endocarditis treated with antistaphylococcal β -lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis. <i>Clinical Microbiology and Infection</i> , 2017, 23, 544-549.	2.8	10
64	Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 924-930.	1.0	10
65	Reply to Letter: Influence of Liver and Kidney Disease on Sofosbuvir Electrophysiological Effects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 933-934.	1.0	0
66	International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines. <i>Clinical Microbiology and Infection</i> , 2017, 23, 736-739.	2.8	29
67	Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact. <i>Journal of Clinical Virology</i> , 2017, 96, 54-59.	1.6	5
68	<i>Candida</i> endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 807-818.	2.0	23
69	Infection of Retained Defibrillator Lead Fragment after Heart Transplant. <i>Clinics and Practice</i> , 2017, 7, 857.	0.6	6
70	Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2016, 18, 319-325.	0.7	4
71	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. <i>BMJ Open</i> , 2016, 6, e009956.	0.8	41
72	Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis. <i>Journal of the American Heart Association</i> , 2016, 5, e003016.	1.6	98

#	ARTICLE	IF	CITATIONS
73	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	1.0	8
74	Antistaphylococcal β -Lactams versus Vancomycin for Treatment of Infective Endocarditis Due to Methicillin-Susceptible Coagulase-Negative Staphylococci: a Prospective Cohort Study from the International Collaboration on Endocarditis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6341-6349.	1.4	7
75	Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant <i>Acinetobacter baumannii</i> infections. Clinical Microbiology and Infection, 2016, 22, 984-989.	2.8	30
76	Clinical significance of hyperhomocysteinemia in infective endocarditis. Medicine (United States), 2016, 95, e4972.	0.4	5
77	Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. International Journal of Antimicrobial Agents, 2016, 48, 61-68.	1.1	28
78	Increased <i>in vitro</i> phenol-soluble modulins production is associated with soft tissue infection source in clinical isolates of methicillin-susceptible <i>Staphylococcus aureus</i> . Journal of Infection, 2016, 72, 302-308.	1.7	13
79	Current features of infective endocarditis in persons on hemodialysis: a prevalence study with case control design from the prospective multicenter SEI cohort. Infection, 2016, 44, 467-474.	2.3	14
80	Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: A single centre, prospective cohort study. Journal of Clinical Virology, 2015, 68, 37-42.	1.6	14
81	Prevalence and significance of two major inherited thrombophilias in infective endocarditis. Internal and Emergency Medicine, 2015, 10, 587-594.	1.0	10
82	Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant <i>Acinetobacter baumannii</i> . Diagnostic Microbiology and Infectious Disease, 2015, 82, 222-226.	0.8	67
83	Recipient-born bloodstream infection due to extensively drug-resistant <i>Acinetobacter baumannii</i> after emergency heart transplant: report of a case and review of the literature. Infection, 2015, 43, 609-613.	2.3	3
84	Response to Letter Regarding Article, "Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis: A Prospective Study From the International Collaboration on Endocarditis". Circulation, 2015, 132, e184-5.	1.6	1
85	Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis. Circulation, 2015, 131, 131-140.	1.6	211
86	Impact of Early Valve Surgery on Outcome of <i>Staphylococcus aureus</i> Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis "Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	2.9	84
87	Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Annals of Hepatology, 2015, 14, 75-82.	0.6	18
88	Differential Antiviral Effects of Pegylated Interferon- α 2a and Pegylated Interferon- α 2b in Chronic Hepatitis C. Clinical Drug Investigation, 2014, 34, 871-878.	1.1	0
89	Combination therapy in severe <i>Acinetobacter baumannii</i> infections: an update on the evidence to date. Future Microbiology, 2014, 9, 773-789.	1.0	69
90	Management of Immunosuppression and Antiviral Treatment before and after Heart Transplant for HIV-Associated Dilated Cardiomyopathy. International Journal of Immunopathology and Pharmacology, 2014, 27, 113-120.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Nosocomial endocarditis: still a challenging diagnosis. <i>Internal and Emergency Medicine</i> , 2014, 9, 715-716.	1.0	3
92	Reply to Huang et al. <i>Clinical Infectious Diseases</i> , 2014, 58, 142-143.	2.9	1
93	Does this patient have Ebola virus disease?. <i>Intensive Care Medicine</i> , 2014, 40, 1738-1741.	3.9	16
94	The Role of Hemostasis in Infective Endocarditis. <i>Current Infectious Disease Reports</i> , 2014, 16, 435.	1.3	19
95	Infective endocarditis due to multidrug resistant gram-negative bacilli: Single centre experience over 5years. <i>European Journal of Internal Medicine</i> , 2014, 25, 657-661.	1.0	17
96	Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). <i>BMC Infectious Diseases</i> , 2014, 14, 230.	1.3	71
97	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2305-2309.	1.3	179
98	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014, 6, 677.	0.8	14
99	Current trends in the management of cardiac implantable electronic device (CIED) infections. <i>Internal and Emergency Medicine</i> , 2013, 8, 465-476.	1.0	16
100	Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant <i>Acinetobacter baumannii</i> : A Multicenter, Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, 349-358.	2.9	322
101	In-Hospital and 1-Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis. <i>JAMA Internal Medicine</i> , 2013, 173, 1495.	2.6	215
102	Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. <i>Journal of Medical Virology</i> , 2013, 85, 1913-1918.	2.5	12
103	Adefovir treatment for chronic hepatitis B in heart transplant recipients. <i>Clinical Transplantation</i> , 2013, 27, E282-8.	0.8	4
104	High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6213-6222.	1.4	85
105	High-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2012, 54, 347-354.	2.9	57
106	Clinical Characteristics and Outcome of Infective Endocarditis Involving Implantable Cardiac Devices. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1727.	3.8	247
107	Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. <i>Infection</i> , 2012, 40, 527-535.	2.3	128
108	Molecular epidemiology and mechanisms of rifampicin resistance in <i>Acinetobacter baumannii</i> isolates from Italy. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 58-63.	1.1	70

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. <i>Digestive and Liver Disease</i> , 2011, 43, 411-415.	0.4	7
110	Global spread of drug-resistant <i>Acinetobacter baumannii</i> : molecular epidemiology and management of antimicrobial resistance. <i>Future Microbiology</i> , 2011, 6, 407-422.	1.0	138
111	A European first: Successful heart transplant in a human immunodeficiency virus-positive recipient. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 845.	0.3	7
112	<i>In vitro</i> activity of multiple antibiotic combinations against <i>Nocardia</i> : relationship with a short-term treatment strategy in heart transplant recipients with pulmonary nocardiosis. <i>Transplant Infectious Disease</i> , 2011, 13, 335-343.	0.7	38
113	Heart Transplantation During Active Infective Endocarditis: Case Report and Review of the Literature. <i>Transplantation Proceedings</i> , 2011, 43, 304-306.	0.3	11
114	Outcome of Treatment With Pegylated Interferon and Ribavirin in Heart Transplant Recipients With Chronic Hepatitis C. <i>Transplantation Proceedings</i> , 2011, 43, 299-303.	0.3	10
115	Association Between Valvular Surgery and Mortality Among Patients With Infective Endocarditis Complicated by Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2239-47.	3.8	175
116	Early Viral Kinetics and Response to Treatment in a Hepatitis C Virus Genotype 5 Infected Patient. <i>Clinics and Practice</i> , 2011, 1, 50-51.	0.6	0
117	Inherited hyper-homocysteinemia as a cause of nonbacterial thrombotic endocarditis. <i>Journal of Heart Valve Disease</i> , 2011, 20, 232-3.	0.5	4
118	Giant endocarditis vegetation on a pace-maker lead. <i>Internal and Emergency Medicine</i> , 2010, 5, 251-252.	1.0	8
119	X-chromosome linked recessive diseases model. , 2010, 2010, 775-8.		3
120	Management of Gram-negative and fungal endocarditis. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, S40-S45.	1.1	59
121	Correlates and Prognostic Value of the First-Phase Hepatitis C Virus RNA Kinetics during Treatment. <i>Clinical Infectious Diseases</i> , 2009, 49, 498-506.	2.9	33
122	Leukocyte interferon- γ and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon. <i>Internal and Emergency Medicine</i> , 2009, 4, 485-490.	1.0	3
123	<i>Rhodococcus equi</i> endocarditis in immunocompetent hosts: report of the first two cases. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 496-497.	1.1	4
124	Safety and efficacy of peginterferon-ribavirin treatment in hepatitis C patients with heart disease. <i>Digestive and Liver Disease</i> , 2009, 41, A41.	0.4	1
125	041 INFECTIVE ENDOCARDITIS ON CARDIAC RHYTHM MANAGEMENT DEVICES: PRELIMINARY STUDY ON THE POSSIBLE PATHOGENIC ROLE OF INHERITED THROMBOPHILIAS. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, S15.	1.1	1
126	Do we still need the aminoglycosides?. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 201-205.	1.1	165

#	ARTICLE	IF	CITATIONS
127	Microsomal triglyceride transfer protein (<i>MTP</i>) â€“493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. <i>Journal of Viral Hepatitis</i> , 2008, 15, 740-746.	1.0	43
128	Current Features of Infective Endocarditis in Elderly Patients. <i>Archives of Internal Medicine</i> , 2008, 168, 2095.	4.3	236
129	Efficacy of Caspofungin Addition to Trimethoprim-Sulfamethoxazole Treatment for Severe <i>Pneumocystis Pneumonia</i> in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2007, 84, 685-688.	0.5	63
130	Infection of intravascular prostheses: how to treat other than surgery. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 42-50.	1.1	16
131	Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant <i>Acinetobacter baumannii</i> isolates producing OXA-58 carbapenemases. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 537-540.	1.1	85
132	Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. <i>Liver International</i> , 2006, 26, 1100-1110.	1.9	28
133	Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-? in chronic hepatitis C patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1349-1357.	1.9	105
134	Defective Synthesis of Granulocyte-Colony Stimulating Factor in Pegylated Interferon-Î± Treated Chronic Hepatitis C Patients with Declining Leukocyte Counts. <i>Antiviral Therapy</i> , 2006, 11, 637-640.	0.6	9
135	Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005, 12, 186-191.	1.0	15
136	Review article: hepatitis C virus-associated steatosis - pathogenic mechanisms and clinical implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 52-55.	1.9	48
137	Mild chronic hepatitis C with steatosis: Which treatment?. <i>Hepatology</i> , 2005, 41, 1198-1198.	3.6	1
138	Interferon-Induced Anti-HBE Seroconversion Correlates with a Th1 Cytokine Shift Following Emergence of Core Promoter Mutations in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1791-1792.	1.1	0
139	<i>Streptococcus bovis</i> Endocarditis and Its Association with Chronic Liver Disease: An Underestimated Risk Factor. <i>Clinical Infectious Diseases</i> , 2004, 38, 1394-1400.	2.9	99
140	Hepatic CD1d Expression in Hepatitis C Virus Infection and Recognition by Resident Proinflammatory CD1d-Reactive T Cells. <i>Journal of Immunology</i> , 2004, 173, 2159-2166.	0.4	122
141	Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment. <i>Journal of Medical Virology</i> , 2004, 73, 33-37.	2.5	6
142	Silent Celiac Disease in Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 901-905.	1.1	54
143	Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-? preparations. <i>Journal of Medical Virology</i> , 2003, 70, 62-73.	2.5	19
144	Right Diaphragm Paralysis Following Cardiac Radiofrequency Catheter Ablation for Inappropriate Sinus Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 783-784.	0.5	57

#	ARTICLE	IF	CITATIONS
145	Risk factors for "major" embolic events in hospitalized patients with infective endocarditis. <i>American Heart Journal</i> , 2003, 146, 311-316.	1.2	114
146	A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. <i>European Heart Journal</i> , 2003, 24, 664-672.	1.0	49
147	Case report: An unusual late relapse of <i>Plasmodium vivax</i> malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 159-60.	0.6	14
148	Normal Erythropoietin Response in Chronic Hepatitis C Patients with Ribavirin-Induced Anaemia. <i>Antiviral Therapy</i> , 2003, 8, 57-63.	0.6	9
149	The prothrombin G20210A polymorphism in patients with myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 603-608.	0.5	8
150	Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. <i>British Journal of Haematology</i> , 2001, 113, 590-595.	1.2	161
151	Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. <i>Clinical Transplantation</i> , 2001, 15, 415-420.	0.8	18
152	Interferon and Ribavirin Treatment for Chronic Hepatitis C May Activate Celiac Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 607-608.	0.2	41
153	Coronary thrombosis and the platelet glycoprotein IIIA gene PLA2 polymorphism. <i>Thrombosis and Haemostasis</i> , 1998, 80, 218-9.	1.8	9